Next‑generation sequencing failure rates in rare tumors: A real‑world single‑institution analysis
Authors:
Open Access
- 18 March 2025
- journal article
- Published by Spandidos Publications in Medicine International
- Vol. 5 (3) , 1-6
Abstract
Reported next‑generation sequencing (NGS) failure rates vary widely and are primarily based on studies of common tumor types. The present study aimed to estimate NGS failure rates in rare tumors and their association with preanalytical variables and sequencing methods in a single institution. Patients with sarcomas, rare carcinomas, and rare melanomas who underwent NGS between January 2022 and October 2023 were eligible for participation in the present study. NGS was performed as whole exome/transcriptome sequencing (WETS) based on hybrid capture or multigene commercial targeted panel. Clinicopathological and NGS‑related data were extracted from clinical charts. Univariable logistic regression models were constructed with the outcome variable NGS failure and the following explanatory variables: Assay, sampling method, tissue type , and storage time. A total of 102 NGS reports from 86 patients with sarcomas (73.3%), rare carcinomas (16.3%), and melanomas (10.5%) were included. The median age of the patients was 40 years [interquartile range (IQR), 23‑61 years]. Samples were obtained by biopsy (51%) and surgery (48%) and were collected from soft tissue (92.1%) or bone (7.9%) lesions. The median storage time was 2.5 months (IQR, 1.3‑4.6 months). Targeted panel and WETS were used in 39.2 and 60.8% of reports, respectively. NGS failure due to insufficient material quantity or quality was observed in 14.7% of tests, corresponding to 4.7% of patients. Repeated testing was successful in 7 out of 8 patients. WETS was significantly associated with a higher probability of NGS failure due to the insufficient quantity or quality of material compared to targeted panel (odds ratio, 11.4; 95% confidence interval, 1.4‑90.4; P=0.022). In summary, our findings suggest that the NGS failure rates in rare tumors are comparable to the rates reported in prevalent neoplasms. WETS can be associated with more frequent NGS failure than targeted panel. Retesting can often overcome the initial NGS testing failure.Keywords
This publication has 13 references indexed in Scilit:
- Challenges to the effectiveness of next-generation sequencing in formalin-fixed paraffin-embedded tumor samples for non-small cell lung cancerAnnals of Diagnostic Pathology, 2023
- Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Clinical Cancer Research, 2023
- Selective multiplexed enrichment for the detection and quantitation of low-fraction DNA variants via low-depth sequencingNature Biomedical Engineering, 2021
- Next-Generation Sequencing in Tumor Diagnosis and TreatmentDiagnostics, 2020
- Precision Oncology in Sarcomas: Divide and ConquerJCO Precision Oncology, 2019
- Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiencesOncotarget, 2017
- The minimal amount of starting DNA for Agilent’s hybrid capture-based targeted massively parallel sequencingScientific Reports, 2016
- Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid TumorsAmerican Journal of Clinical Pathology, 2016
- Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ MalignanciesCancers, 2015
- Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS)Molecular Oncology, 2015